Department of the Cardiovascular Medicine, the Fourth People's Hospital of Chengdu, Chengdu, Sichuan - China.
Health Management Center, Sichuan Provincial People's Hospital, Chengdu, Sichuan - China.
Arq Bras Cardiol. 2022 Sep;119(3):372-379. doi: 10.36660/abc.20210799.
Atherosclerosis is the main cause for most cardiovascular diseases, and new biomarkers for this condition are always needed. Peptidase M20 domain containing 1 (PM20D1) is associated with both lipid metabolism and obesity. However, no study focuses on the role of PM20D1 in carotid atherosclerosis.
The present study aimed to investigate the role of PM20D1 in carotid atherosclerosis patients.
The present prospective observational study contained a total of 231 carotid atherosclerosis patients, who went to our department between July 2018 and December 2019. Blood samples and medical characteristics were also obtained from 231 healthy individuals with the same body mass index distribution of carotid atherosclerosis patients. Serum PM20D1 was determined using enzyme-linked immunosorbent assay. Clinical and demographic characteristics of all patients were collected, including age, sex, body mass index and medical history. Levels of C-reactive protein, tumor necrosis factor, homocysteine, as well as total cholesterol, triglyceride, high-density leptin cholesterol and low-density leptin cholesterol were recorded. Statistical analysis was conducted using the SPSS software, with p<0.05 as statistically different.
Serum PM20D1 levels were markedly lower in carotid atherosclerosis patients when compared to the healthy control, which were significantly lower in severe carotid atherosclerosis patients and carotid atherosclerosis/stroke patients. Patients with unstable plaques showed markedly lower PM20D1 when compared to patients with stable plaques. No significant difference was found among carotid atherosclerosis patients with different body mass index. Patients with higher PM20D1 levels showed significantly lower expression of C-reactive protein, tumor necrosis factor, homocysteine, triglyceride, total cholesterol and low-density leptin cholesterol. PM20D1 was negatively correlated with C-reactive protein, tumor necrosis factor, homocysteine, total cholesterol and low-density leptin cholesterol in carotid atherosclerosis patients, and could be used as a biomarker for severe carotid atherosclerosis patients or carotid atherosclerosis patients with stroke. Sex, tumor necrosis factor, homocysteine and PM20D1 were risk factors for carotid atherosclerosis.
PM20D1 was decreased in carotid atherosclerosis patients and was associated with severity, plaque stability, and levels of C-reactive protein, tumor necrosis factor, homocysteine, triglyceride, total cholesterol and low-density leptin cholesterol in carotid atherosclerosis patients.
动脉粥样硬化是大多数心血管疾病的主要病因，因此我们一直需要新的生物标志物来进行诊断。肽酶 M20 结构域包含蛋白 1（PM20D1）与脂代谢和肥胖有关。然而，目前还没有研究关注 PM20D1 在颈动脉粥样硬化中的作用。
本研究旨在探讨 PM20D1 在颈动脉粥样硬化患者中的作用。
本前瞻性观察研究共纳入 231 例颈动脉粥样硬化患者，均于 2018 年 7 月至 2019 年 12 月在我院就诊。同时选取 231 例与颈动脉粥样硬化患者具有相同体重指数分布的健康个体作为对照，收集其血液样本和临床特征。采用酶联免疫吸附试验检测血清 PM20D1 水平。收集所有患者的临床和人口统计学特征，包括年龄、性别、体重指数和既往病史。记录 C 反应蛋白、肿瘤坏死因子、同型半胱氨酸、总胆固醇、三酰甘油、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇水平。采用 SPSS 软件进行统计学分析，p<0.05 为差异有统计学意义。
与健康对照组相比，颈动脉粥样硬化患者的血清 PM20D1 水平明显降低，且严重颈动脉粥样硬化患者和颈动脉粥样硬化/卒中患者的血清 PM20D1 水平明显更低。不稳定斑块患者的 PM20D1 水平明显低于稳定斑块患者。不同体重指数的颈动脉粥样硬化患者之间无明显差异。PM20D1 水平较高的患者其 C 反应蛋白、肿瘤坏死因子、同型半胱氨酸、三酰甘油、总胆固醇和低密度脂蛋白胆固醇表达水平明显更低。PM20D1 与颈动脉粥样硬化患者的 C 反应蛋白、肿瘤坏死因子、同型半胱氨酸、总胆固醇和低密度脂蛋白胆固醇呈负相关，可作为严重颈动脉粥样硬化患者或伴有卒中的颈动脉粥样硬化患者的生物标志物。性别、肿瘤坏死因子、同型半胱氨酸和 PM20D1 是颈动脉粥样硬化的危险因素。
PM20D1 在颈动脉粥样硬化患者中减少，与严重程度、斑块稳定性以及颈动脉粥样硬化患者的 C 反应蛋白、肿瘤坏死因子、同型半胱氨酸、三酰甘油、总胆固醇和低密度脂蛋白胆固醇水平相关。
